[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR0114986A - Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida. - Google Patents

Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida.

Info

Publication number
BR0114986A
BR0114986A BR0114986-5A BR0114986A BR0114986A BR 0114986 A BR0114986 A BR 0114986A BR 0114986 A BR0114986 A BR 0114986A BR 0114986 A BR0114986 A BR 0114986A
Authority
BR
Brazil
Prior art keywords
compound
substituted
alkyl
pharmaceutically acceptable
hydrate
Prior art date
Application number
BR0114986-5A
Other languages
English (en)
Inventor
Nathan Bryan Mantlo
Ivan Collado Cano
Samuel James Dominianni
Garret Jay Junior Etgen
Cristina Garcia-Paredes
Richard Duane Johnston
Michael Edward Letourneau
Michael John Matinelli
Daniel Ray Mayhugh
Ashraf Saeed
Richard Craig Thompson
Xiadong Wang
David Scott Coffey
Christopher Randall Schmid
Jeffrey Thomas Vicenzi
Yanping Xu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR0114986A publication Critical patent/BR0114986A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/06Compounds containing any of the groups, e.g. semicarbazides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/22Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having nitrogen atoms of amidino groups further bound to nitrogen atoms, e.g. hydrazidines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02Compounds containing any of the groups, e.g. carbazates
    • C07C281/04Compounds containing any of the groups, e.g. carbazates the other nitrogen atom being further doubly-bound to a carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cultivation Of Plants (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, USO DE PELO MENOS UM COMPOSTO OU UM SAL, SOLVATO OU HIDRATO DESTE FARMACEUTICAMENTE ACEITáVEIS, E, PROCESSO PARA PREPARAR TRIAZOLONA A PARTIR DE UMA ACIL SEMICARBAZIDA". A presente invenção está direcionada aos compostos representados pela seguinte fórmula estrutural e seus sais, solvatos e hidratos farmaceuticamente aceitáveis, R1 é um grupo substituído ou não substituído selecionado de alquila C~ 1~-C~ 8~, aril-alquila C~ 0-2~, heteroaril-alquila C~ 0-2~, cicloalquilarila C~ 3~-C~ 6~ alquila C~ 0-2~ ou fenila. W é O ou S. R2 é H ou um grupo substituído ou não substituído selecionado de alquila C~ 1~-C~ 6~, cicloalquila C~ 3~-C~ 6~ e heteroarila. X é um ligador de alquileno C~ 2~-C~ 5~ em que um átomo de carbono do ligador pode ser substituído com O, NH ou S. Y é C, O, S, NH ou uma ligação simples. Além disso, E é (CH~ 2~)~ n~COOH, em que n é 0, 1, 2 ou 3, ou C(R3)(R4)A, em que A é um grupo funcional ácido tal como carboxila, sulfonamida substituído ou não substituído por carboxamida ou tetrazol substituído ou não substituído. R3 é H, alquila C~ 1~-C~ 5~, alcóxi C~ 1~-C~ 5~ saturados ou insaturados. Adicionalmente, R4 é H, halo, um grupo substituído ou não substituído selecionado de alquila C~ 1~-C~ 5~, alcóxi C~ 1~-C~ 5~, cicloalquila C~ 3~-C~ 6~, arilalquila C~ 0~-C~ 4~ e fenila ou R3 e R4 são combinados para formar um cicloalquila C~ 3~-C~ 4~.
BR0114986-5A 2000-11-10 2001-11-09 Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida. BR0114986A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24731700P 2000-11-10 2000-11-10
PCT/US2001/042928 WO2002038553A2 (en) 2000-11-10 2001-11-09 Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists

Publications (1)

Publication Number Publication Date
BR0114986A true BR0114986A (pt) 2003-09-23

Family

ID=22934453

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0114986-5A BR0114986A (pt) 2000-11-10 2001-11-09 Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida.

Country Status (35)

Country Link
US (3) US7304062B2 (pt)
EP (1) EP1335908B1 (pt)
JP (1) JP4243101B2 (pt)
KR (1) KR100839705B1 (pt)
CN (1) CN1479728A (pt)
AR (1) AR031305A1 (pt)
AT (1) ATE386026T1 (pt)
AU (3) AU2859202A (pt)
BR (1) BR0114986A (pt)
CA (1) CA2421154A1 (pt)
CY (1) CY1107388T1 (pt)
CZ (1) CZ20031283A3 (pt)
DE (1) DE60132799T2 (pt)
DK (1) DK1335908T3 (pt)
EA (1) EA006920B1 (pt)
EC (1) ECSP034595A (pt)
ES (1) ES2300378T3 (pt)
HK (1) HK1058790A1 (pt)
HR (1) HRP20030365A2 (pt)
HU (1) HUP0301655A2 (pt)
IL (2) IL154840A0 (pt)
MX (1) MXPA03004141A (pt)
MY (1) MY157884A (pt)
NO (1) NO20032059L (pt)
NZ (1) NZ524569A (pt)
PE (1) PE20020693A1 (pt)
PL (1) PL362692A1 (pt)
PT (1) PT1335908E (pt)
SI (1) SI1335908T1 (pt)
SK (1) SK5412003A3 (pt)
SV (1) SV2003000727A (pt)
TW (1) TW200716572A (pt)
UA (1) UA82048C2 (pt)
WO (1) WO2002038553A2 (pt)
ZA (1) ZA200302517B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002347985A1 (en) 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
CN1662487A (zh) 2002-06-19 2005-08-31 伊莱利利公司 酰胺连接基过氧化物酶体增殖物激活受体调节剂
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
FR2866339B1 (fr) * 2004-02-18 2006-05-05 Pf Medicament Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
ES2391461T3 (es) * 2004-07-27 2012-11-27 F. Hoffmann-La Roche Ag Compuestos de benciltriazolona utilizados como inhibidores no nucleósidos de transcriptasa inversa
KR100803481B1 (ko) * 2004-07-27 2008-02-14 에프. 호프만-라 로슈 아게 비-뉴클레오사이드 역전사효소 억제제로서의벤질트라이아졸론 화합물
US8293778B2 (en) 2004-07-27 2012-10-23 Roche Palo Alto Llc Heterocyclic antiviral compounds
AU2005272389B2 (en) * 2004-08-11 2011-08-04 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminobenzoic acid derivative
WO2006068199A1 (ja) * 2004-12-22 2006-06-29 Mochida Pharmaceutical Co., Ltd. 代謝的に安定な3-オキシ-1,2,4-トリアゾール誘導体
TW200640453A (en) * 2005-01-28 2006-12-01 Lilly Co Eli Formulations and dosing regimen for PPAR-α modulators
FR2882750B1 (fr) 2005-03-03 2007-05-11 Pierre Fabre Medicament Sa Derives de 1,2,4-triazines, leur preparation et leur application en therapeutique humaine
KR20070116644A (ko) * 2005-03-23 2007-12-10 교린 세이야꾸 가부시키 가이샤 신규 환상 아미노페닐알칸산 유도체
EP1863777A1 (en) * 2005-03-24 2007-12-12 F.Hoffmann-La Roche Ag 1,2,4 -triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
WO2007126043A1 (ja) * 2006-04-27 2007-11-08 Mitsubishi Tanabe Pharma Corporation チアゾール環を含むカルボン酸誘導体の医薬用途
EP2129667A2 (en) * 2007-02-23 2009-12-09 Eli Lilly And Company Peroxisome proliferator activated receptor modulators
EP2142520A1 (en) 2007-03-29 2010-01-13 F. Hoffmann-Roche AG Non-nucleoside reverse transcriptase inhibitors
WO2010002712A2 (en) * 2008-06-30 2010-01-07 3M Innovative Properties Company Method of crystallization
CN101643451B (zh) * 2008-08-07 2013-03-06 浙江海正药业股份有限公司 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法
WO2010064633A1 (ja) 2008-12-01 2010-06-10 田辺三菱製薬株式会社 チアゾール環を含むカルボン酸誘導体およびその医薬用途
US8575430B2 (en) * 2010-03-02 2013-11-05 Nunhems, B.V. Hybrid artichoke variety NUN 4006 AR
US20110167512A1 (en) * 2009-03-02 2011-07-07 Nunhems B.V. Hybrid artichoke variety nun 4006 ar
DE102010001064A1 (de) * 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
US20100245582A1 (en) * 2009-03-25 2010-09-30 Syclipse Technologies, Inc. System and method of remote surveillance and applications therefor
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US8648233B2 (en) * 2010-09-20 2014-02-11 Nunhems B.V. Hybrid artichoke variety NUN 4021 AR
US8669420B2 (en) 2012-02-29 2014-03-11 Nunhems B.V. Hybrid artichoke variety NUN 4060 AR
EP2822931B1 (en) * 2012-03-09 2017-05-03 Inception 2, Inc. Triazolone compounds and uses thereof
DK2935228T3 (en) * 2012-12-20 2017-10-30 Inception 2 Inc TRIAZOLONE COMPOUNDS AND APPLICATIONS THEREOF
WO2015035059A1 (en) * 2013-09-06 2015-03-12 Inception 2, Inc. Triazolone compounds and uses thereof
RU177130U1 (ru) * 2017-11-29 2018-02-09 Владимир Алексеевич Коннов Плита изоляционная облицовочная
CN115398657A (zh) 2020-04-10 2022-11-25 松下知识产权经营株式会社 热电转换元件、热电转换组件、接合材料和热电转换元件的制造方法
CN112774869B (zh) * 2020-12-25 2022-09-16 厦门紫金矿冶技术有限公司 黄铁矿抑制剂及其制备和在铜铅锌多金属硫化矿中的应用
CN114853686B (zh) * 2021-08-23 2023-06-20 中国药科大学 三氮唑酮类化合物及其医药用途
CN115894379A (zh) * 2022-01-20 2023-04-04 中国药科大学 海因类化合物及其医药用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
DE19517505A1 (de) * 1995-05-12 1996-11-14 Bayer Ag Sulfonylamino(thio)carbonyltriazolin(thi)one mit Aryloxy- oder Arylthio-Substituenten
EP0858457A1 (de) * 1995-10-20 1998-08-19 Dr. Karl Thomae GmbH 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung
AU9462198A (en) * 1997-10-17 1999-05-10 Yamanouchi Pharmaceutical Co., Ltd. Amide derivatives or salts thereof
AU1120599A (en) * 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
PE20011010A1 (es) * 1999-12-02 2001-10-18 Glaxo Group Ltd Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano
US6573287B2 (en) 2001-04-12 2003-06-03 Bristo-Myers Squibb Company 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method
USPP14578P2 (en) * 2002-09-23 2004-03-09 Plant Sciences, Inc. Artichoke plant named ‘PS-MSC0003’

Also Published As

Publication number Publication date
DE60132799T2 (de) 2009-03-19
EA006920B1 (ru) 2006-04-28
CA2421154A1 (en) 2002-05-16
HK1058790A1 (en) 2004-06-04
ES2300378T3 (es) 2008-06-16
US20090062358A1 (en) 2009-03-05
SV2003000727A (es) 2003-01-13
AU2006202811A1 (en) 2006-07-20
ECSP034595A (es) 2003-06-25
NO20032059D0 (no) 2003-05-08
NO20032059L (no) 2003-06-24
US7868225B2 (en) 2011-01-11
MXPA03004141A (es) 2003-08-19
IL154840A0 (en) 2003-10-31
UA82048C2 (uk) 2008-03-11
AU2002228592B2 (en) 2006-04-27
CZ20031283A3 (cs) 2003-09-17
KR20030048133A (ko) 2003-06-18
US20040102500A1 (en) 2004-05-27
HRP20030365A2 (en) 2003-08-31
PE20020693A1 (es) 2002-08-05
JP2004513166A (ja) 2004-04-30
SK5412003A3 (en) 2004-01-08
US7304062B2 (en) 2007-12-04
DE60132799D1 (de) 2008-03-27
AU2859202A (en) 2002-05-21
KR100839705B1 (ko) 2008-06-19
EP1335908B1 (en) 2008-02-13
PL362692A1 (en) 2004-11-02
JP4243101B2 (ja) 2009-03-25
SI1335908T1 (sl) 2008-08-31
AR031305A1 (es) 2003-09-17
MY157884A (en) 2016-08-01
PT1335908E (pt) 2008-05-08
AU2002228592B8 (en) 2006-08-24
CN1479728A (zh) 2004-03-03
EP1335908A2 (en) 2003-08-20
IL154840A (en) 2009-09-22
DK1335908T3 (da) 2008-06-02
US20090044299A1 (en) 2009-02-12
CY1107388T1 (el) 2012-12-19
WO2002038553A3 (en) 2003-05-01
ZA200302517B (en) 2004-06-30
WO2002038553A2 (en) 2002-05-16
NZ524569A (en) 2006-05-26
TW200716572A (en) 2007-05-01
HUP0301655A2 (hu) 2003-12-29
ATE386026T1 (de) 2008-03-15
EA200300558A1 (ru) 2004-02-26

Similar Documents

Publication Publication Date Title
BR0114986A (pt) Composto, composição farmacêutica, uso de pelo menos um composto ou um sal, solvato ou hidrato deste farmaceuticamente aceitáveis, e, processo para preparar triazolona partir de uma acil semicarbazida.
TW200716576A (en) Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
BRPI0818193B8 (pt) composto, composição farmacêutica, e, uso de um composto
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BR0109011A (pt) Composto, processo para preparação e uso do mesmo, método para produzir um efeito inibidor de ibat em um animal de sangue quente, e, composição farmacêutica
HRP20090627T1 (hr) Inhibitori hcv ns3 proteaze
HRP20020175B1 (en) N-heterocyclikc derivatives as nos inhibitors
AR035548A1 (es) Compuestos organicos
DE602004031258D1 (de) Polycyclische mittel zur behandlung von infektione
PE20081583A1 (es) Agentes antibacterianos derivados de compuestos carbonilamino
TW200744587A (en) Azaindole derivatives exhibiting PGD2 receptor antagonism
BR0315815A (pt) Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
ES2191484T3 (es) Compuestos heterociclicos como inhibidores de enzimas de rotamasa.
BRPI0414738A (pt) derivados de ácido acético substituìdos
BR0313846A (pt) Derivados de dioxano-2-alquilcarbamatos, sua preparação e sua aplicação em terapêutica
CA2421114A1 (en) 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith
BRPI0406500A (pt) processo farmacêutico e compostos preparados pelo mesmo
BRPI0415220A (pt) processo de produção de amida carboxìlica e derivados da mesma
TW200745104A (en) Multikinase inhibitor
AU2003207432A1 (en) Urea linker derivatives for use as ppar modulators
BRPI0409471B8 (pt) processo para preparação de 2-cianopirrolidinas n-substituídas
CA2423007A1 (en) Spiro derivatives and adhesion molecule inhibitors containing the same as effective ingredients
AR046310A1 (es) Compuestos nucleosidicos para el tratamiento de enfermedades virales. composiciones farmaceuticas.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.